Collaboration Plan Clause Samples

Collaboration Plan. The Collaboration Plan as described in Schedule 18 (Technical Requirements) is specified in Appendix 11, as attached and forming part of this Schedule, and shall be amended or supplemented by the Contractor as required in accordance with Schedule 18 and in accordance with the procedure set out in Schedule 5 (Design and Plan Certification Process and Review Procedure).

Collaboration Plan. The research and preclinical Development activities of the Parties with respect to the Collaboration Program will be described in a “Collaboration Plan,” an initial version of which is attached hereto as Exhibit 2.1(b). The Collaboration Plan will include a budget for the remaining portion of the Calendar Year in which this Agreement is executed and the next succeeding Calendar Year, and a projected budget for the next Calendar Year thereafter or until the end of the Collaboration Program Term if shorter. The Collaboration Plan will be reviewed as necessary at each meeting of the JSC, and at any other time upon the request of either Party, and will be modified as appropriate at the direction of the JSC to reflect material scientific, commercial and other developments. In all events, the Collaboration Plan will be consistent and not conflict with the terms of this Agreement.

Collaboration Plan. The initial Collaboration Plan is described in Exhibit D. The Steering Committee shall prepare an amended Collaboration Plan no later than [*] and every [*] thereafter, during the Contract Period. Such amended Collaboration Plans shall be appended to Exhibit D and made part of this Agreement.

Collaboration Plan. (a) The Parties shall establish a research pre-clinical and clinical development plan for each Collaboration Product, as may be supplemented and amended from time to time by the Joint Steering Committee, as described in Section 2.2.2.(a) (each, a “Collaboration Plan”). The initial Collaboration Plan for the Initial Collaboration Products shall be attached hereto as Exhibit 3.1.2.(a).1, Exhibit 3.1.2.(a).2, Exhibit 3.1.2.(a).3 and Exhibit 3.1.2.(a).4. Subject to Servier’s exercise of the Servier Collaboration Option in accordance with Section 3.1.1.(c), the Parties shall within ninety (90) days of the exercise of the Servier Confidential

Collaboration Plan. 2.1 The fee schedule accompanying the Collaboration Plan at “Section E – Compensation” shall be updated as follows: 2.1.1 The activity descriptions, deliverables, and associated payments for Milestones 2-4 shall be updated as reflected in Appendix A. ​ 2.1.2 Activity descriptions, deliverables, and associated payments for new Milestones 5-8 shall be updated as reflected in Appendix A.

Collaboration Plan. The Parties have prepared an initial Collaboration Plan for the Initial Collaboration Product and the research activities for TCL and improvements to antigen presenting cells that is attached to the Agreement as Appendix 1.20. Unless decided otherwise by the JSC, each initial Collaboration Plan for additional Collaboration Products, Roche Products, SQZ Products and TCL Products will be drafted by the JRDT and presented to the JSC for approval. Subsequently, each Collaboration Plan will be updated annually by the JRDT and approved by the JSC. No later than [********] before the beginning of each Calendar Year, the JSC shall review each Collaboration Plan and may approve amendments the Collaboration Plan. Any such changes shall be reflected in written amendments to the Collaboration Plan. Each Collaboration Plan will set forth (a) the scope of the Research and Development Program and the resources that will be dedicated to the activities contemplated within the scope of the Research and Development Program, including the responsibilities of each Party, (b) specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JSC as research progresses, and (c) any reimbursable or shared expenses for such activities. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Collaboration Plan. 2.1.1 During the term of this Agreement, the parties shall collaborate with each other in accordance with a written plan (the “Collaboration Plan”), to be adopted by the parties. The initial Collaboration Plan is attached hereto as Exhibit E and will include the following: (a) Intematix to use its best effort to optimize the performance of its phosphor with SemiLEDs’ LED dies having 390 – 470 mn wavelength, or such other wavelengths, as a pump source for both cold and warm light applications (“Phosphors”). (b) SemiLEDs to use its best effort to optimize the performance of its LED dies (“LED Chips”) using Phosphors. (c) Each of Intematix and SemiLEDs shall cooperate to develop the highest performing One Package Solution with the Products. (d) Each of Intematix and SemiLEDs shall ensure that each of their Products delivered under this Agreement are of the highest quality and performance. 2.1.2 The Collaboration Plan may be amended from time to time.

Collaboration Plan. 39 Schedule 5....................................................................40 Supply and Distribution of Novartis Products.............................40 Schedule 6....................................................................48 Part I - Collaboration Committee.........................................48 Part II - Executive Committee............................................48 Schedule 7....................................................................49

Collaboration Plan. There are multiple components to the annual production of approximately * FE compounds in the form of approximately * libraries per year and these are very well established and understood by the collaboration team based on the previous four years. The key components in the FE process can be segmented into the following categories: * and *. These same steps are also similar for HF and LL production, however, the range of available parameters and responsibility may be different from FE. For FE and LL, Pfizer will provide * and * while ArQule will be responsible for * and *. For HF, Pfizer will be responsible for * as well as provide *. ArQule will be responsible for the * and *. A summary of the research plan details are given in Table 1.